NCT02609581View on ClinicalTrials.gov

Tolerability of SLIT With LAIS® Mites Allergoid Tablets

CompletedOBSERVATIONAL
Enrollment

192

Participants

Timeline

Start Date

December 1, 2015

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Allergic Rhinitis
Interventions
DRUG

Sublingual Immunotherapy with tablets (mites)

Sublingual immunotherapy involves putting a tablet of allergen extracts (mites) under the tongue to swallow the extract.

All Listed Sponsors
lead

University Hospital of Cologne

OTHER

NCT02609581 - Tolerability of SLIT With LAIS® Mites Allergoid Tablets | Biotech Hunter | Biotech Hunter